About Peripheral Arterial Disease:
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 18 million people in the United States suffer from PAD, a common circulatory problem in which narrowed arteries reduce blood flow to the limbs. Estimates suggest that anywhere from 12 to 20 percent of individuals over the age of 60 are living with PAD.
About PQ Bypass:
PQ Bypass Inc. is a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD). Operated by recognized leaders in the medical device industry, including veterans from Boston Scientific, Philips, Medtronic, Abbott and Johnson & Johnson, PQ Bypass devices are built upon nearly a decade of research and patented technological advancement. The company’s physician-driven innovations include the Detour procedure for percutaneous femoropopliteal bypass and the proprietary TORUS stent graft, the first new stent graft developed for use in the SFA in 15 years.
PQ Bypass is currently sponsoring two multicenter IDE trials, DETOUR2 and TORUS2, to evaluate the safety and effectiveness of its technology platform in two distinct patient populations and build upon the body of clinical evidence collected in the DETOUR1 and TORUS1 studies.
PQ Bypass is recognized by MedTech Outlook magazine as one of the Top 10 Cardiovascular Companies of 2019 and earned Frost and Sullivan’s European Technology Innovation award in 2017. The DETOUR system and the TORUS Stent Graft are limited by federal law to investigational use only and are not available for sale.
Back to HCB News
